***Background.*** Hepatitis B is an important public health issue in endemic areas, especially with the HIV epidemic. In the USA, hepatitis B and HIV coinfection represent approximately 6-10% of people living with HIV/AIDS. We report the experience with HIV-Hepatitis B-coinfected patients in our clinic

***Methods.*** Of 1011 na•ve HIV patients enrolled at IDP from June 2004 to December 2011 who had available chart for review and who were started on antiretrovirals, those with HepBsAG+ were studied. Demographics, antiretroviral treatment and hepatitis B and HIV markers were abstracted. SAS9.2 was used for analysis. p \< 0.05 was considered significant.

***Results.*** There were 89HbsAg+ patients. Of those, 76(86%)were male, 73(82%) were black, and 58(65%) were men having sex with men or bisexuals. The age at HIV diagnosis was 34.4 years old. The majority 82 (92%) had a positive antigen at presentation to the clinic and 5 became positive during follow up. The baseline CD4 count was 87.16 + /-123 cells/mL. Among the 63(70%) with Hepatitis B viral load at baseline, 12(20%) had undetectable viral load and 32(51%) had high viral load (greater than 1 million). Among those, 48(55.2%) had an undetectable viral load at the last visit, and 7(8%) developed immunity with HepBsAb + ; among the 22 who had a HBsAb checked at follow up, a third (7/22)were positive; 6 of the 7 was on tenofovir/emtricitabine and 1 on emtricitabine containing regimen . Among those who had undetectable HepB viral load, 83% were on tenofovir/emtricitabine, and 10% on a lamivudine or emtricitabine-containing regimen. Among the 5 patients who became HbsAg+ after enrolling in the clinic, all were male and 3 received HepB immunization. One had acute HepB and resolved, another developed chronic HepB and became immune, another transferred care, and 2 had no further follow up on their HepB.

***Conclusion.*** In the late antiretroviral era, half of the chronic active hepatitis B coinfected patients had undetectable hepatitis B viral load at the last follow up and 8% developed immunity. Further studies with more uniform hepatitis B markers in follow up will help determine if a large proportion of chronically infected patients on dual hepatitis B therapy will develop immunity. Greater efforts are needed to ensure susceptible patients are immunized for Hepatitis B.
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